834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial

BACKGROUND: BRIGHTE is an ongoing global study evaluating the gp120 attachment inhibitor fostemsavir (FTR) in heavily treatment-experienced (HTE) adults with multidrug resistant (MDR) HIV-1 unable to form a viable antiretroviral (ARV) regimen. An estimated 2 million people living with HIV-1 have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Chabria, Shiven, De Wit, Stephane, Pierce, Amy, Shepherd, Bronagh M, Warwick-Sanders, Michael, Du, Fangfang, Wang, Marcia, Clark, Andrew, Ackerman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644983/
http://dx.doi.org/10.1093/ofid/ofab466.1030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644983/
http://dx.doi.org/10.1093/ofid/ofab466.1030

Ejemplares similares